Pentadecapeptide BPC-157 reverses neuronal damage and restores function in rat models of stroke, psychosis, and spinal cord injury.

Central nervous system (CNS) disorders like stroke, schizophrenia, and spinal cord injury present immense therapeutic challenges, often resulting in permanent functional deficits. For instance, stroke caused by vascular occlusion leads to sustained neuronal damage and cognitive impairment. Current treatments have limited efficacy in reversing this damage. Similarly, models of schizophrenia involve complex dysregulation of dopamine and nitric oxide systems, which are difficult to manage. Spinal cord compression injuries frequently result in paralysis with poor recovery prospects. This review investigates the stable gastric pentadecapeptide BPC 157, a compound with known pleiotropic beneficial effects, as a potential single therapeutic agent capable of addressing the complex, multi-systemic damage seen across these distinct CNS pathologies through its influence on the gut-brain and brain-gut axes.

This paper reviewed several preclinical studies in rats investigating the effects of BPC 157. In a stroke model, rats underwent bilateral clamping of the common carotid arteries, with BPC 157 administered during reperfusion to assess its impact on brain damage and functional recovery. For schizophrenia-like models, BPC 157 was tested against catalepsy induced by L-NG-nitro arginine methyl ester (L-NAME) and haloperidol, and its interaction with agents like amphetamine, apomorphine, and MK-801 was examined. In a spinal cord injury model, rats with spinal cord compression received BPC 157 therapy to evaluate functional recovery from conditions like tail paralysis and nerve damage.

BPC 157 demonstrated significant therapeutic effects across all reviewed CNS injury models. In the stroke model, BPC 157 administration counteracted the induced brain damage, resolving neuronal deficits and restoring memory, locomotion, and coordination. This was supported by changes in specific gene expression in hippocampal tissues. For schizophrenia-like symptoms, BPC 157 resolved catalepsy induced by both L-NAME and haloperidol, indicating its ability to modulate both nitric oxide and dopamine system disturbances. It effectively counteracted dopamine receptor blockade, supersensitivity, over-release, and nigrostriatal damage. In the spinal cord injury model, BPC 157 therapy led to advanced healing and functional recovery.

The review highlights that BPC 157 counteracted a wide array of disturbances, including encephalopathies, vascular occlusion, dopamine system disruptions (blockade, supersensitivity, over-release), and nitric oxide system imbalances, suggesting a powerful and versatile neuroprotective and restorative capacity.

Written by TitrateLab, separately from the study summarized above.